Membranoproliferative Glomerulonephritis
- Author: Pranay Kathuria, MD, MBBS, FACP, FASN; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
Background
Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of chronic nephritis that occurs primarily in children and young adults. This entity refers to a pattern of glomerular injury based on characteristic histopathologic findings, including: (1) proliferation of mesangial and endothelial cells and expansion of the mesangial matrix (see the first image below), (2) thickening of the peripheral capillary walls by subendothelial immune deposits and/or intramembranous dense deposits (see the second image below), and (3) mesangial interposition into the capillary wall, giving rise to a double-contour or tram-track appearance on light microscopy (see the third image below).
Membranoproliferative glomerulonephritis (MPGN) type I. Glomerulus with lobular accentuation from increased mesangial cellularity. A segmental increase occurs in the mesangial matrix, and the peripheral capillary walls are thickened (hematoxylin and eosin stained section; original magnification × 250). Courtesy of John A. Minielly, MD. 
Membranoproliferative glomerulonephritis (MPGN) type I. Immunofluorescent stained section. Intense, peripheral, glomerular, capillary loop deposition of immunoglobulin G (IgG) in an interrupted linear pattern corresponding to extensive subendothelial immune deposits (original magnification × 400). Courtesy of John A. Minielly, MD. 
Membranoproliferative glomerulonephritis (MPGN) type I. Glomerulus with mesangial interposition producing a double contouring of basement membranes, which, in areas, appear to surround subendothelial deposits (Jones silver methenamine–stained section; original magnification × 400). Courtesy of John A. Minielly, MD. MPGN can be subdivided into idiopathic and secondary types. The secondary types are more common than the idiopathic types and are diagnosed by carefully reviewing clinical features, laboratory data, and renal histopathology. Types I, II, and III are the 3 distinctive types of idiopathic MPGN that are described based on immunofluorescence staining, ultrastructural appearance, and complement profiles. The light microscopy features are mostly indistinguishable among the 3 types.
Clinical presentation is similar among the 3 MPGN types, but they manifest somewhat different mechanisms of complement activation and predisposition to recur in renal transplants.[1] Conversion from one type to another is not reported. Familial forms of all 3 MPGN types have been described.
See also Pediatric Nephritis, Tubulointerstitial Nephritis, and Radiation Nephritis.
Pathophysiology
The normal complement system consists of the classic and alternative pathways. The classic pathway is activated by the interaction of C1 with an antigen-antibody complex. This interaction results in the formation of C4b2a, which is the classic pathway C3b convertase. The alternative pathway utilizes C3 and factors B and D to form the alternative pathway convertase C3b,Bb.
Small amounts of C3b are constantly being formed in the circulation, which are inactivated by factors H and I. The binding of C3b to a foreign antigen decreases its affinity for factor H and allows for the formation of increasing amounts of the alternate pathway convertase. The classic and alternate pathway convertases cause C3 activation, forming C3a and C3b. C3b is an opsonin itself, and C3 convertase facilitates the activation of the terminal pathway and the formation of the membrane attack complex C5b-9.
Hypocomplementemia in MPGN
Hypocomplementemia is a characteristic finding with all types of membranoproliferative glomerulonephritis (MPGN). Low C3 levels are present in approximately 75% of patients with this condition. Although hypocomplementemia bears no relation to the clinical course or prognosis of MPGN, it may play a role in initiating glomerular inflammation and injury. Hypocomplementemia results from increased catabolism and decreased C3 synthesis. The decreased C3 synthesis is likely caused by the negative feedback by C3 breakdown products.
Three nephritic antibodies are described in MPGN that play a role in the development of hypocomplementemia[2, 3] : (1) nephritic factor of the classic pathway (NFc or C4NeF), (2) nephritic factor of the amplification loop (NFa or C3NeF), and (3) nephritic factor of the terminal pathway (NFt).
The reason for genesis of nephritic antibodies is not known. These autoantibodies are not specific for MPGN and are also seen in poststreptococcal and lupus glomerulonephritis. NFc stabilizes the classic pathway C3 convertase C4b,2a. This nephritic factor does not cause C3 conversion unless C4b,2a production is ongoing. NFa (C3NEF) is an autoantibody to C3b,Bb. The binding of NFa to C3b,Bb stabilizes the complex, preventing degradation by its normal inactivators, resulting in complement activation and chronic consumption of C3.
NFt stabilizes the alternative pathway properdin-dependent C3/C5 convertase (C3Bb2,Bb,P) and leads to C3 activation and consumption. The consumption of C3 caused by NFt is much slower than that caused by NFa. NFt also activates the terminal complement components forming C5b-C9, the membrane attack complex.
MPGN type I
Circulating immune complexes are present in approximately 33% of patients with MPGN type I. In all patients with type I disease, immune complexes are found in the mesangium and subendothelial spaces, and they trigger complement activation and the release of cytokines and chemokines. The release of inflammatory mediators causes an influx of inflammatory cells and leads to mesangial and endothelial cell proliferation. Most patients with circulating immune complexes do not develop MPGN; thus, additional pathogenic factors (eg, nature of the antigen, size of complexes, type and charge on antibodies, local glomerular factors) must play a role.
In addition to circulating immune complexes becoming entrapped in the glomerular basement membrane (GBM), experimental evidence indicates that complexes may be formed in situ when antigens adhere to the GBM, and antibodies subsequently bind to these antigens. Formation of such immune complexes triggers the same cascade as described above.
Activation of complement and the resulting hypocomplementemia may cause defective clearance of circulating immune complexes. The nephritic factor of the classic pathway (ie, NFc or C4NeF) is found in approximately 15% of patients. This nephritic factor stabilizes the classic pathway C3 convertase C4b,2a and potentiates C3 activation and consumption. The role of this nephritic factor in the pathogenesis of MPGN type I is unclear. Approximately 20% of patients have the nephritic factor of the terminal pathway.
MPGN type II (or dense deposit disease)
MPGN type II, or dense deposit disease, is a separate entity that has been conventionally classified with MPGN because of the similarities of light microscopic appearance. The pathogenesis of MPGN type II is not known.
This disease is systemic, as evidenced by dense deposits in the kidney, splenic sinusoids, Bruch membrane of the retina, as well as its association with acquired partial lipodystrophy.[4, 5] MPGN type II also has a high incidence of recurrence in renal allografts. The chemical composition and origin of the dense deposits are not known, although bright staining with thioflavine-T and wheat germ agglutinin suggests the presence of N-acetyl-glucosamine. No circulating immune complexes are observed in MPGN type II.
Dense deposit disease is associated with multiple complement abnormalities, including a persistent reduction of C3 levels. One hypothesis is that the dense deposits cause complement activation.[6] This hypothesis is supported by the tram-track distribution of C3 deposits along the basement membrane.
NFa is present in 80% of patients with dense deposit disease. NFa stabilizes the alternative pathway convertase and results in complement activation and chronic C3 consumption. Deficiency of factor H, functionally defective factor H, mutant factor H binding site of C3 (Marder disease), and presence of inhibitory or blocking factor H antibodies, described in MPGN, may lead to an accumulation of the alternative pathway convertase and chronic C3 consumption.
Partial lipoid dystrophy (PLD) is associated commonly with MPGN type II and the presence of NFa. Adipocytes produce adipsin, which is identical to complement factor D and is responsible for activating the preconvertase C3b,Bb. NFa causes a lysis of adipocytes that produce adipsin, and the distribution of fat atrophy in partial lipoid dystrophy follows variations in the amount of adipsin produced by adipocytes. By analogy, NFa may cause damage to glomerular cells that produce complement.
MPGN type III
The glomerular deposits contain C3, C5, and properdin, indicating activation of the alternative complement pathway. Signs of activation of the classic pathway are minimal, and circulating immune complexes do not appear to play a role in the genesis of this variant.
Changes in the capillary wall are hypothesized to be the primary event leading to activation of the complement pathway. This hypothesis is supported by the deposition of C3Bb2,Bb convertase components in the basement membrane. The deposits of convertase and membrane attack complex may lyse the basement membrane and stimulate new membrane formation. NFt is present in 60-80% of patients with MPGN type III. NFt stabilizes the alternative pathway properdin-dependent C3/C5 convertase (C3Bb2,Bb,P) and also activates the terminal complement components, forming C5b-C9 (ie, the membrane attack complex).
A familial form of MPGN type III with an autosomal dominant pattern of inheritance has been identified with genetic linkage to band 1q31-32.[7] Genes in this area of chromosome 1 code for proteins that regulate the C3 convertase activity.
Etiology
Immune complex–mediated conditions, autoimmune diseases, chronic infections, chronic and recovered thrombotic microangiopathies, paraprotein deposition diseases, and malignant neoplasms associated with a membranoproliferative pattern of injury are summarized below.
Immune complex–mediated disease
Idiopathic forms of membranoproliferative glomerulonephritis or of unknown association include membranoproliferative glomerulonephritis (MPGN) type I, MPGN type II (or dense deposit disease) and partial lipoid dystrophy (PLD), and MPGN type III.
Autoimmune diseases
Systemic lupus erythematosus (SLE), Sjögren syndrome, rheumatoid arthritis, inherited complement deficiencies (in particular, C2 deficiency), scleroderma, and celiac disease are associated with a membranoproliferative pattern of renal injury.
Chronic infections
Chronic viral, bacterial, protozoal, and Mycoplasma infections as well as chronic liver disease (cirrhosis and alpha1-antitrypsin deficiency) are associated with a membranoproliferative pattern of renal injury, as follows:
- Viral – Hepatitis B, hepatitis C,[8] and cryoglobulinemia type II
- Bacterial – Endocarditis, infected ventriculoatrial (or jugular) shunt, multiple visceral abscesses, leprosy
- Protozoal – Malaria, schistosomiasis
Chronic and recovered thrombotic microangiopathies
The following are chronic and recovered thrombotic microangiopathies associated with a membranoproliferative pattern of renal injury[9] :
- Healing phase of hemolytic uremic syndrome (HUS) and/or thrombotic thrombocytopenic purpura (TTP)
- Syndromes of circulating antiphospholipid (anticardiolipin) antibodies
- Radiation nephritis
- Nephropathy associated with bone marrow transplantation
- Sickle cell anemia and polycythemia
- Transplant glomerulopathy
Paraprotein deposition diseases
Paraprotein deposition diseases that are associated with a membranoproliferative pattern of renal injury include the following:
- Glomerulonephropathies associated with cryoglobulinemia type I
- Waldenström macroglobulinemia
- Immunotactoid glomerulopathy
- Immunoglobulin light chain or heavy chain deposition diseases
- Fibrillary glomerulonephritis
- Monoclonal gammopathy of unknown significance
Malignant neoplasms
Lymphoma, leukemia, and carcinoma are associated with a membranoproliferative pattern of renal injury.
Epidemiology
United States statistics
Membranoproliferative glomerulonephritis (MPGN) is observed in 6-12% of US patients receiving renal biopsies to evaluate glomerular diseases. This entity accounts for 7% of children and 12% of adults with idiopathic nephrotic syndrome.
Globally, MPGN causes a significant proportion of the cases of nephritis among patients in nonindustrialized countries. For example, in Mexico, MPGN accounts for 40% of all patients with nephritis. Most of these patients have type I disease; MPGN type II is uncommon. However, the incidence of MPGN type I is decreasing progressively in developed countries, which may be explained by a change in environmental factors, especially a decline in infections.
In an investigation of the changing patterns of adult primary glomerular disease occurrence in a single region of the United Kingdom, Hanko et al analyzed the results of 1844 native renal biopsies taken between 1976 and 2005 (inclusive) and found the presence of primary glomerulonephritis was revealed in 49% of the biopsies, with the most common forms being immunoglobulin A (IgA) nephropathy (38.8%).[10] Other common forms were membranous nephropathy (29.4%), minimal-change disease (MCD) (9.8%), MPGN type 1 (9.6%), and focal segmental glomerulosclerosis (FSGS) (5.7%). The incidence of IgA nephropathy increased significantly over the study period, whereas the occurrence of membranous nephropathy decreased.[10]
Racial, sexual, and age differences in incidence
In the United States, MPGN predominantly affects the white population. Type I disease affects women more often than men, whereas a nearly equal sex distribution is seen in MPGN type II.
The idiopathic forms of MPGN are more common in children and young adults (range, 6-30 y). Isolated reports of involvement in patients as young as 2 years and as old as 80 years are noted in the literature. Secondary types of MPGN predominate among adults.[11]
Prognosis
The main predictors of an adverse outcome in membranoproliferative glomerulonephritis (MPGN) are nephrotic syndrome and hypertension at presentation, low glomerular filtration rate (GFR) at 1 year, and older age.[12, 13] Histologic characteristics of crescent formation, interstitial fibrosis, tubular atrophy, and multiple sclerotic glomeruli indicate a poor prognosis. However, hypocomplementemia is not a predictor of disease severity or prognosis.
MPGN type I with nephrotic syndrome is a progressive disease, with 50% of patients developing end-stage renal disease (ESRD) after 10 years and 90% of patients developing ESRD after 20 years. MPGN type I without nephrotic proteinuria has a 10-year renal survival rate of 85%.
MPGN type II is generally more aggressive than type I disease and has a median renal survival rate of 5-12 years. ESRD develops in 50% of the patients within 10 years of diagnosis.
There are very limited data on outcomes with MPGN type III. Iitaka et al found that 7 patients who were followed for 9-17 years maintained their renal function over this period,[14] whereas Anders et al reported 4 of 8 patients in their series developed ESRD.[15] When Braun et al compared therapy with alternate-day corticosteroids in 21 patients with type I disease and 25 patients with type III disease (followed for a minimum of 5 y), the investigators found that patients with MPGN type III had a greater decline in GFR, but there was no difference in the number of patients reaching ESRD in the 2 groups.[16]
Patient Education
Ensure that patients with progressive azotemia receive timely education regarding renal replacement options. In addition, recommend that patients have frequent follow-up visits with a dietitian, which are essential to ensuring patient diet compliance.
The authors suggest the reader see the Mayo Clinic - Kidney Transplant Information Website for further information.
For patient information, see Chronic Kidney Disease, and Kidney Transplant.
Lorenz EC, Sethi S, Leung N, et al. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. Feb 3 2010;[Medline].
Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens. Jul 2005;14(4):396-403. [Medline].
Varade WS, Forristal J, West CD. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis. Sep 1990;16(3):196-206. [Medline].
Levy Y, George J, Yona E, et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res. Aug 1998;18(1):55-60. [Medline].
Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. May 2007;16(3):204-12. [Medline].
Licht C, Schlötzer-Schrehardt U, Kirschfink M, et al. MPGN II--genetically determined by defective complement regulation?. Pediatr Nephrol. Jan 2007;22(1):2-9. [Medline].
Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol. Aug 2002;13(8):2052-7. [Medline].
Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV/HCV-co-infected patients. AIDS. Jun 19 2009;23(10):1219-26. [Medline].
Skerka C, Licht C, Mengel M, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. Sep 2009;46(14):2801-7. [Medline].
Hanko JB, Mullan RN, O'Rourke DM, et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. Oct 2009;24(10):3050-4. [Medline].
Rennke HG. Secondary membranoproliferative glomerulonephritis. Kidney Int. Feb 1995;47(2):643-56. [Medline].
Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. Feb 1983;74(2):175-92. [Medline].
Cansick JC, Lennon R, Cummins CL, et al. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis. Nephrol Dial Transplant. Nov 2004;19(11):2769-77. [Medline].
Iitaka K, Moriya S, Nakamura S, et al. Long-term follow-up of type III membranoproliferative glomerulonephritis in children. Pediatr Nephrol. May 2002;17(5):373-8. [Medline].
Anders D, Agricola B, Sippel M, et al. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch A Pathol Anat Histol. Oct 27 1977;376(1):1-19. [Medline].
Braun MC, West CD, Strife CF. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis. Dec 1999;34(6):1022-32. [Medline].
Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. Jul 2009;72(1):46-54. [Medline].
Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. Sep 2009;20(9):2055-64. [Medline].
D'Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. Mar 1995;25(3):361-9. [Medline].
Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. Mar 1999;106(3):347-54. [Medline].
Garini G, Allegri L, Vaglio A, et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int. Apr-Jun 2005;20(2):71-80. [Medline].
Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. Dec 1994;46(6):1700-4. [Medline].
Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. Nov 1994;46(5):1255-63. [Medline].
Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis. Oct 2003;42(4):631-57. [Medline].
Abbas NA, Pitt MA, Green AT, et al. Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Nephrol Dial Transplant. May 1999;14(5):1272-5. [Medline].
Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology. Aug 1995;109(2):540-6. [Medline].
Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. Mar 17 1994;330(11):751-6. [Medline].
Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. Aug 2003;18(8):1573-80. [Medline].
Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. May 15 2003;101(10):3818-26. [Medline].
Arikan H, Koc M, Cakalagaoglu F, et al. Histopathological changes and tumour necrosis factor-alpha, transforming growth factor-beta and tenascin expression in patients with primary type I membranoproliferative glomerulonephritis in remission. Nephrology (Carlton). Apr 2009;14(2):219-26. [Medline].
Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int. Oct 1997;52(4):871-85. [Medline].
Jones G, Juszczak M, Kingdon E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant. Dec 2004;19(12):3160-4. [Medline].
Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. Sep 2007;18(9):2447-56. [Medline].
Tarshish P, Bernstein J, Tobin JN, et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. Mar 1992;6(2):123-30. [Medline].
McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore). Nov 1985;64(6):401-24. [Medline].
Takeda A, Niimura F, Matsutani H. Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children. Nippon Jinzo Gakkai Shi. Jun 1995;37(6):330-5. [Medline].
Harmankaya O, Basturk T, Ozturk Y, et al. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol. 2001;33(3):583-7. [Medline].
Zauner I, Bohler J, Braun N, et al. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant. 1994;9(6):619-22. [Medline].
Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. May 2005;16(5):1392-403. [Medline].
Haddad M, Lau K, Butani L. Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus. Pediatr Nephrol. Oct 2007;22(10):1787-91. [Medline].
Print
